Australian-developed pill could ease distressing behaviours in dementia patients

An Australian-developed supplier to easiness nan debilitating symptoms of dementia is being trialled successful respective states passim nan country.

Dementia tin lead to behavioural and psychological changes, affecting a mostly of patients during their illness, causing them distress and putting unit connected family and caregivers.

"We deliberation of dementia arsenic a nonaccomplishment of memory, but that's obscurity adjacent arsenic difficult aliases frustrating to look aft than changes successful characteristic and behaviour, including agitation and aggression," said Associate Professor Michael Woodward, Austin Health Aged Care and Memory Clinic Director.

The caller supplier called KNX100 is designed arsenic an replacement to antipsychotic medications which transportation important side-effects and are considered a past edifice erstwhile non-pharmaceutical interventions fail.

"It's important that we're capable to create caller treatments that are targeted and that don't person nan side-effects peculiarly drowsiness that we encounter," Trial Principal Investigator Dr Peter de Wet said .

"We request smart medications that don't conscionable sedate a person, don't conscionable chemically restrain them," Associate Professor Woodward said.

A full of 60 dementia patients who are surviving astatine location are being recruited to participate successful tests crossed Queensland, New South Wales, Victoria and South Australia.

The supplier has already been shown successful earlier tests to beryllium safe and tolerable.

"It interferes pinch an enzyme (in nan brain) that we cognize is associated pinch nan signalling pathway that leads to agitation, aggression and different symptoms that are distressing to patients pinch dementia," he said.

The invention originated from investigation astatine nan University of Sydney which led to rotation retired institution Kinoxis.

"We're providing a solution that we judge is simply a important unmet need,"

"We purpose to further create and put successful this to return it arsenic acold arsenic imaginable towards approval," said Hugh Alsop, Kinoxis Therapeutics CEO.

Patients successful Victoria, New South Wales and South Australia tin find retired much on the study's website.

DOWNLOAD THE 9NEWS APP: Stay crossed each nan latest successful breaking news, sport, authorities and nan upwind via our news app and get notifications sent consecutive to your smartphone. Available connected the Apple App Store and Google Play.